Skip to main content
Journal cover image

Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).

Publication ,  Journal Article
Kunadian, V; Giugliano, RP; Newby, LK; Zorkun, C; Guo, J; Bagai, A; Montalescot, G; Braunwald, E; Califf, RM; Van de Werf, F; Armstrong, PW ...
Published in: Am J Cardiol
April 15, 2014

Early administration of glycoprotein IIbIIIa inhibitors results in improved angiographic parameters, including thrombolysis in myocardial infarction (TIMI) flow grade, corrected TIMI frame count, and TIMI myocardial perfusion grade (TMPG) among patients with ST-segment elevation myocardial infarction. Whether the same is true in the setting of non-ST-segment elevation acute coronary syndrome is unknown. The goal of the early glycoprotein IIbIIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) angiographic substudy was to compare angiographic outcomes among patients with non-ST-segment elevation acute coronary syndrome who were administered early routine versus delayed provisional eptifibatide. Of 9,406 patients in the EARLY ACS trial, 2,066 patients were included in the angiographic substudy (early routine eptifibatide [n=1,042] or early placebo [n=1,024] with delayed provisional eptifibatide after angiography and before percutaneous coronary intervention [PCI]). The angiographic substudy primary end point was the incidence of TMPG 3 before and after PCI. TMPG 3 before (43.7% vs 44.9%, p=0.58) and after PCI (52.4% vs 50.1%, p=0.73) was similar for early routine versus delayed provisional eptifibatide, respectively. Angiographic procedural complications consisting of a composite of loss of side branch, abrupt vessel closure, distal embolization, and no reflow occurred less frequently in early routine group versus delayed provisional group (9.3% vs 13.6%, respectively, p=0.01). In the EARLY ACS angiographic substudy, the use of early routine eptifibatide resulted in fewer angiographic procedural complications. These data provide support for the use of eptifibatide in the catheterization laboratory during high-risk cases merely to prevent angiographic procedural complications.

Duke Scholars

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

April 15, 2014

Volume

113

Issue

8

Start / End Page

1297 / 1305

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Retrospective Studies
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kunadian, V., Giugliano, R. P., Newby, L. K., Zorkun, C., Guo, J., Bagai, A., … Gibson, C. M. (2014). Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Am J Cardiol, 113(8), 1297–1305. https://doi.org/10.1016/j.amjcard.2014.01.404
Kunadian, Vijay, Robert P. Giugliano, L Kristin Newby, Cafer Zorkun, Jianping Guo, Akshay Bagai, Gilles Montalescot, et al. “Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).Am J Cardiol 113, no. 8 (April 15, 2014): 1297–1305. https://doi.org/10.1016/j.amjcard.2014.01.404.
Kunadian V, Giugliano RP, Newby LK, Zorkun C, Guo J, Bagai A, et al. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Am J Cardiol. 2014 Apr 15;113(8):1297–305.
Kunadian, Vijay, et al. “Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).Am J Cardiol, vol. 113, no. 8, Apr. 2014, pp. 1297–305. Pubmed, doi:10.1016/j.amjcard.2014.01.404.
Kunadian V, Giugliano RP, Newby LK, Zorkun C, Guo J, Bagai A, Montalescot G, Braunwald E, Califf RM, Van de Werf F, Armstrong PW, Harrington R, Gibson CM. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Am J Cardiol. 2014 Apr 15;113(8):1297–1305.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

April 15, 2014

Volume

113

Issue

8

Start / End Page

1297 / 1305

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Retrospective Studies
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans